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Proteasomes are the primary sites for protein degra-
dation in mammalian cells. Each proteasome particle
contains two chymotrypsin-like, two trypsin-like, and
two caspase-like proteolytic sites. Previous studies sug-
gest a complex network of allosteric interactions be-
tween these catalytic and multiple regulatory sites. We
used positional scanning combinatorial substrate li-
braries to determine the extended substrate specificity
of the caspase-like sites. Based on this analysis, several
new substrates were synthesized, the use of which con-
firmed earlier observations that caspase-like sites (often
termed postglutamyl peptide hydrolase) cleave after as-
partates better than after glutamates. Highly selective
inhibitors of the caspase-like sites were also generated.
They stimulated trypsin-like activity of yeast 20 S pro-
teasomes up to 3-fold but not when binding of the inhib-
itor to the caspase-like sites was prevented in a mutant
carrying an uncleaved propeptide. Although substrates
of the caspase-like sites allosterically inhibit the chy-
motrypsin-like activity, inhibitors of the caspase-like
sites do not affect the chymotrypsin-like sites. Further-
more, when caspase-like sites were occupied by the un-
cleaved propeptide or inhibitor, their substrates still
inhibited the chymotrypsin-like activity. Thus, occu-
pancy of the caspase-like sites stimulates the trypsin-
like activity of proteasomes, but substrates of the
caspase-like sites inhibit the chymotrypsin-like activity
by binding to a distinct noncatalytic site.
The majority of proteins in mammalian cells are degraded by
the 26 S proteasome (1). This large (2.4-MDa) ATP-dependent
complex consists of the 20 S proteasome and one or two 19 S
regulatory complexes (2, 3). The 20 S particle is a hollow
cylinder composed of four stacked rings. Two inner -rings are
identical in subunit composition, and each -ring contains
three different proteolytic sites, which differ in their specificity
(4). The chymotrypsin-like site cleaves peptide bonds after hy-
drophobic residues, and the trypsin-like site cuts after basic
residues, whereas the third site cuts preferentially after acidic
residues (see Ref. 5 for references). This last “postacidic” site
had been generally termed postglutamyl peptide hydrolase
(PGPH)1 (6), but we found that it cleaves after aspartates in
fluorogenic substrates of caspases and therefore suggested the
name “caspase-like” (5). All of these active sites cleave peptide
bonds via a nucleophilic attack of the hydroxyl group of the
N-terminal threonine of the catalytic -subunit (7–9). The ac-
tive subunits are generated from larger precursors that contain
a propeptide at their N terminus, which block the active sites
until removed autocatalytically during assembly of the 20 S
particle (10). If the catalytic threonine is mutated to an alanine,
this autoprocessing does not occur, and both substrate binding
and catalysis are impossible, since the active sites are occupied
by the 8–9-residue-long propeptides (11, 12).
The catalytic sites are located on the inner surface of this
cylindrical particle, within the central chamber, and access of
substrates to them is controlled by the narrow, gated channels
in the -rings (13, 14). When these channels are closed, 20 S
proteasomes are in a latent state, and peptides added exog-
enously are hydrolyzed only very slowly. The rate of peptide
hydrolysis dramatically increases upon opening of these gated
channels. Such opening can be triggered by the ATPases of the
19 S complexes (14) or by PA28/PA26 proteasome activator
complexes (15), by mutation (13), or by various chemical treat-
ments, such as low concentrations of SDS (16, 17).
We previously found that hydrophobic peptide substrates of
the chymotrypsin-like sites can stimulate peptide hydrolysis by
all active sites of the latent 20 S proteasome (5, 16). These
effects were shown to involve binding of hydrophobic peptides
to a distinct noncatalytic regulatory site and to result from
peptide-induced opening of the channel in the -rings, because
opening of the channels in the -ring by a variety of treatments
(e.g. deletions of N-terminal tails of -subunits, treatment with
SDS, and association with PA26 activators or 19 S regulatory
complexes) abolished this activation (16). On the other hand,
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activation of proteolysis by hydrophobic peptides was reduced
by potassium ions at concentrations similar to those found
inside cells, through inhibition of spontaneous opening of these
channels (16).
Another allosteric effect that we uncovered was that the
substrates of the caspase-like sites cause a noncompetitive
inhibition of the chymotrypsin-like activity (5). Because the Ki
value for this allosteric inhibition was similar to the Km of
these acidic peptides for the caspase-like sites, we concluded
that the inhibition of the chymotrypsin-like activity was caused
by the binding of these acidic peptides to the caspase-like sites
(5). However, Myung et al. (19) and Schmidtke et al. (18) were
unable to prevent these allosteric effects by blocking the
caspase-like site and therefore concluded that acidic peptides
inhibit the chymotrypsin-like activity by binding to a distinct
regulatory site. On the other hand, these investigators used
inhibitors of the caspase-like sites that either were weak (18) or
showed only moderate selectivity (19). Thus, it remains unclear
whether substrates of the caspase-like sites inhibit the chymo-
trypsin-like activity by binding to the caspase-like or a distinct
regulatory site(s). In order to study the mechanism of this
allosteric inhibition, we here characterize the extended sub-
strate specificity of the caspase-like site and design a peptide
analogue inhibitor that matches the sequence of the best sub-
strate. Such an inhibitor could be used to probe interactions
between the caspase-like and trypsin-like sites.
Positional scanning substrate libraries have proven to be
useful tools to define the specificity of “classical” proteolytic
enzymes including caspases (20) and many serine and cysteine
proteases (21–23). These studies led to the design of selective
substrates and inhibitors of different caspases (20). Recently,
these libraries have been used to study the specificity of pro-
teasomes and its modulation by different PA28 activators (24),
but without assigning cleavage patterns to individual active
sites. To address the specificity of the individual active sites,
Nazif and Bogyo (25) used positional scanning irreversible in-
hibitor libraries with the vinyl sulfone pharmacophore. This
approach, although it led to the development of selective inhib-
itors of the trypsin-like sites, is limited from a synthetic point
of view, because it can use only 2 amino acids, glutamine and
asparagine, in the P1 position.
In this study, we use positional scanning libraries, in com-
bination with subunit-selective inhibitors, to define further the
specificity of the individual active sites of proteasome. Specifi-
cally, we defined substrate-binding preferences of the caspase-
like sites in proteasomes and then designed several improved
substrates and inhibitors of the caspase-like sites. Application
of these inhibitors led to the discovery of novel allosteric inter-
actions between the caspase- and trypsin-like sites and re-
solved whether the inhibition of the chymotrypsin-like activity
by acidic peptides involves their binding to the caspase-like
sites.
EXPERIMENTAL PROCEDURES
Enzymes and Inhibitors—20 and 26 S proteasomes from rabbit mus-
cle and 20 S particles (wild type and 1T1A mutant) from yeast Sac-
charomyces cerevisiae (strains SUB61 and MHY1157, respectively)
were purified as described previously (16). Recombinant human
caspase-1, -3, and -8 were produced and purified as described (26).
Recombinant PA26 was a kind gift of Drs. C. Hill and A. Duff (Univer-
sity of Utah). YU102 (Ac-GPFL-ex) was purchased from Affinity Re-
search Products (Exeter, UK). NLVS was a kind gift of Dr. Matt Bogyo
(University of California San Francisco), and AEBSF (Pefablock SC)
was purchased from Roche Applied Science. Fluorogenic substrates of
proteasome (except those synthesized in this study) and caspases were
from Bachem (King of Prussia, PA). Protected amino acids used in
substrate and inhibitor synthesis were from Calbiochem-Novabiochem
(La Jolla, CA) or Advanced ChemTech (Louisville, KY).
Analysis of Proteasome Specificity with Positional Scanning Librar-
ies—A positional scanning synthetic combinatorial library (PS-SCL)
with the general structure Ac-X-X-X-Asp-amc designed to determine
the specificities of the human caspase family and Granzyme B (20) has
been used in this study to characterize the specificity of the caspase-like
sites in proteasomes. 20 S proteasome samples (3 g/well) were added
to reaction mixtures containing 50 mM Tris-HCl, pH 7.5, 1 mM dithio-
threitol, and 100 M substrate mix in a total volume of 100 l. Under
these conditions, the final concentration of each individual compound
was 0.25 M. Production of 7-amino-4-methylcoumarin (AMC) was
monitored as described (20). In some experiments, proteasomes were
preincubated for 30 min at room temperature with 1 M NLVS and 0.5
mM AEBSF to inactivate the chymotrypsin-like and trypsin-like sites,
respectively.
Synthesis of Substrates—The P4-P2 portion of all substrates was
synthesized using Fmoc-based solid phase peptide synthesis on the
Wang resin. After acidic cleavage (trifluoroacetic acid/CH2Cl2), the
P4-P2 portions were condensed with either Asp(OtBu)-amc, Glu(OtBu)-
amc, or Leu-amc under the agency of PyBOP and diisopropylethyl-
amine, followed by final acidic deprotection (in case of Asp and Glu) to
give, after preparative HPLC, the desired fluorogenic substrates. As-
p(OtBu)-amc, Glu(OtBu)-amc, and Leu-amc were prepared as described
by Knight (27).
Synthesis of Peptide Aldehyde Inhibitors—Peptides Ac-APnL and
Z-PnL were synthesized on a solid phase using standard Fmoc-based
peptide chemistry (28). A fully protected semicarbazone derivative of
Asp-al, Fmoc-Asp(OtBu)-semicarbazone, was prepared from Fmoc-As-
p(OtBu)-COOH using Weinreb amide methodology (29), after which the
Fmoc group was removed by a 1,8-diazabicyclo[5.4.0]undec-7-ene/
octanethiol mixture as described (30). The P4-P2 peptide fragments
were coupled to Asp(OtBu)-semicarbazone in solution as described (31).
The tBu protecting group was removed by a 25% solution of trifluoro-
acetic acid in dichloromethane (32). The semicarbazone group was
removed by a mixture of methanol, acetic acid, and formaldehyde (32).
The resulting aldehydes were purified to homogeneity by preparative
HPLC. The structure of all inhibitors synthesized was confirmed by
NMR and mass spectrometry.
Assays of Proteasome Activity—The cleavage of fluorogenic peptide
substrates was measured in 96-well plates by continuously monitoring
the fluorescence of the reaction product (free AMC). The rates of reac-
tion were determined from the slopes of the resulting reaction progress
curves. 20 S proteasome activity was assayed in 50 mM Tris-HCl, pH
7.5, 1 mM dithiothreitol. The buffer used for assays of 26 S proteasomes
also contained 40 mM KCl, 5 mM MgCl2, 0.5 mM ATP or AMP-PNP, and
50 g/ml bovine serum albumin. Proteasomes from rabbit muscle were
assayed at 37 °C, and yeast proteasomes were assayed at 30 °C. PA26
was always present at a 4-fold molar excess over 20 S proteasomes.
Measuring Ki of Peptide Aldehyde Inhibitors—Proteasomes were
added to a 100 M solution of Ac-nLPnLD-amc containing different
concentrations of inhibitors. Steady state rates in the presence (Vi) or
absence (Vo) of inhibitor were determined from the slopes of the reaction
progress curves. Apparent Ki (Ki(app)) was determined as the reciprocal
slope of the plot of Vo/Vi against the concentration of the inhibitor
according to the equation Vo/Vi  1  [S]/Ki(app). True Ki was then
determined from the following equation: Ki  Ki(app)/(1  [S]/Km). Inhi-
bition of caspase-1, -3, and -8 by Z-PnLD-al and Ac-APnLD-al was
monitored using continuous fluorometric assays as described (33, 34).
Briefly, appropriate dilutions of enzyme were combined with Km con-
centrations of substrate in the absence or presence of several concen-
trations of the inhibitor of interest, in a total volume of 100 l. Liber-
ation of AMC was monitored for up to 1 h at room temperature. The
assay was conducted in a buffer containing 100 mM HEPES, 10%
sucrose, 0.1% CHAPS, 10 mM dithiothreitol, pH 7.5. The substrates
used were Ac-WEHD-amc for caspase-1 and Ac-DEVD-amc for
caspase-3 and caspase-8. Reaction rates were fit by nonlinear regres-
sion to the Michaelis-Menten equation for competitive inhibition to
obtain a value for the inhibition constant Ki.
RESULTS
Characterization of the Specificity of the Caspase-like Site by
Position-scanning Libraries—Positional scanning synthetic
combinatorial libraries (PS-SCL) of general structure Ac-X-X-
X-Asp-amc (20, 35) were developed and successfully used to
map the specificity of caspases in the P2–P4 positions. Since
proteasomes can cleave standard caspase substrates (5), we
used these libraries to characterize the specificity of the
caspase-like sites in the proteasomes. This PS-SCL is composed
Substrates and Inhibitors of Proteasome Caspase-like Sites35870
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of three separate sublibraries (P2, P3, and P4). In each subli-
brary, one position is defined with one of 20 amino acids,
whereas the remaining two positions contain approximately
equimolar mixtures of all amino acids (20). 20 S proteasomes
from rabbit muscle were incubated simultaneously with all
three sublibraries (20 samples each) in a 96-well plate, and the
cleavage of the Asp-amc bond was followed by monitoring the
fluorescence of released AMC.
This analysis revealed that in the P2 position, the caspase-
like sites in proteasomes strongly prefer bulky hydrophobic
residues (Nle, Phe, Trp, Tyr, and Leu) (Fig. 1a). This finding is
surprising, because the x-ray diffraction of yeast proteasome
did not reveal a pronounced substrate-binding pocket for the P2
residue in any active site of the yeast or archaeal proteasomes
(4, 8). Cleavages after most other amino acid residues, except
Pro and Asp, were also observed, but they occurred at lower
rates. In the P3 position (Fig. 1b), nonaromatic hydrophobic
(Leu, Nle, and Pro) and Ala residues were preferred, whereas
Asp and Lys caused significantly lower cleavage rates. Protea-
somes showed low selectivity for the P4 position of the sub-
strate (Fig. 1c).
In order to confirm that these cleavages were performed by
the caspase-like site, we repeated the screen after inactivation
of the chymotrypsin-like site with the irreversible inhibitor
NLVS (16). The trypsin-like sites were simultaneously inacti-
vated with another irreversible inhibitor, AEBSF (36). When
these sites were inactive (NLVS- and AEBSF-treated protea-
somes cleaved standard substrates of chymotrypsin-like and
trypsin-like sites at 2–5% of the control rates), the pattern of
selectivity against this library (Fig. 1, d–f) was not different
from that of the control proteasomes (Fig. 1, a–c). Therefore,
the great majority of cleavages in this library are indeed per-
formed by the caspase-like sites.
Interestingly, NLVS- and AEBSF-treated proteasomes
cleaved libraries at 2-fold higher rates than control particles
(Fig. 1). This observation is surprising, because we have previ-
ously shown that treatment of proteasomes with NLVS and
AEBSF does not enhance the caspase-like activity (16, 36). In
the previous study, preincubation of proteasomes with these
irreversible inhibitors was followed by the removal of the ex-
cess of the unreacted inhibitor by dilution or dialysis. In the
present study, concentrations of inhibitors were not reduced
prior to the addition of substrates. Hydrophobic peptides stim-
ulate peptide hydrolysis by the caspase-like site and two other
sites by binding to the noncatalytic sites (16). Because NLVS is
hydrophobic (it contains 3 leucine residues), we tested whether
NLVS can also enhance substrate hydrolysis by the caspase-
like sites by reversible binding to the noncatalytic sites. When
we removed excess NLVS by dilution or dialysis so that only
NLVS irreversibly attached to the chymotrypsin-like sites re-
mained, no activation of the caspase-like sites was observed
(16). When 1 M NLVS (same concentration as used in the
experiments on Fig. 1) was added back to the mixture of sub-
strates and proteasomes with blocked chymotrypsin-like sites,
it still stimulated cleavage of substrates by the caspase-like
sites 2-fold (data not shown). Thus, enhanced rates of library
cleavage in the presence of NLVS and AEBSF are due to
binding of NLVS to the noncatalytic regulatory sites.
These studies were performed with latent 20 S proteasomes
in which the gates in the -rings are largely in the closed
conformation. Consequently, in these particles, substrate entry
through this channel rather than their hydrolysis at the active
sites is the rate-limiting step (16). To exclude the possibility
that the results of the screen were affected by difference in
substrate access to the proteolytic chamber, we repeated this
analysis under several conditions where the channels are
mainly in an open state. Screens were performed in the pres-
ence of 0.01% SDS or the hydrophobic peptides, Suc-FLF-mna
and Suc-LLVY-mna, both of which trigger gate opening (16). As
expected, the overall activity of the proteasomes increased con-
siderably, but similar patterns of substrate preference were
found (data not shown). Thus, the original screen with latent
20 S proteasomes (Fig. 1) indeed revealed subsite preferences
of the caspase-like site and did not reflect the relative abilities
of the substrates to enter the particles.
New Substrates of the Caspase-like Sites—The caspase-like
sites of the proteasome are currently the most difficult to assay.
The most commonly used substrate Z-LLE-na is cleaved not
only at the Glu-na bond but also at Leu-Glu bond (5). Cleavage
of this substrate results in the release of potentially carcino-
genic -naphthylamine, which is less fluorescent than AMC
used in substrates of the other active sites. Furthermore,
-naphthylamine fluoresces at different wavelengths and thus
requires different filters than those used for AMC, which may
cause inconvenience to investigators using filter-based flu-
orometers. To eliminate some of these problems, -naphthyla-
mine was replaced by AMC. However, the resulting Z-LLE-amc
was cleaved at a 600-fold lower rate than Z-LLE-na (data not
shown). Previously, we used the standard caspase substrate,
Ac-YVAD-amc, to assay the caspase-like site in proteasomes
(5). It was cleaved more than 50-fold faster than Z-LLE-amc
but significantly slower than standard substrates of the chy-
motrypsin- and trypsin-like sites (5). Another disadvantage of
Ac-YVAD-amc was that it was also cleaved by the proteasome
(probably by the chymotrypsin-like site) N-terminally of the
Asp-amc bond (data not shown). Because of this clear need for
more sensitive and more specific substrates of the caspase-like
site, we used the results of the screens with PS-SCL to design
new fluorogenic substrates.
Our goal was to generate substrates cleaved rapidly at the
FIG. 1. Substrate specificity of the caspase-like sites of the
proteasome. Cleavage of Ac-XXX-Asp-amc PS-SCL by 20 S protea-
somes from rabbit muscle was assayed in the absence of inhibitors (a–c)
or after a 30-min preincubation with inhibitors of the chymotrypsin-like
(1 M NLVS) and trypsin-like (0.5 mM AEBSF) sites (d–f).
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Asp-amc amide bond, but not at any of the peptide bonds. Since
analysis of the specificity by PS-SCL revealed that the caspase-
like site prefers hydrophobic residues in the P2 and P3 posi-
tions, it was possible that any newly designed substrates might
also be cleaved after these residues by the chymotrypsin- or
caspase-like sites. In order to prevent such cleavage, we took
advantage of the fact that a Pro residue, when present in the P3
position, allowed rapid cleavages at the Asp-amc bond (Fig. 1b),
although it almost completely prevented such cleavages when
present in the P2 position (Fig. 1a). In addition, we had ob-
served that several fluorogenic peptides with a Pro in the P2
position and a hydrophobic residue in P1 are not cleaved by the
chymotrypsin-like sites.2 Therefore, a Pro in P3 should not only
allow rapid cleavage after aspartate; it also should prevent
cleavage after hydrophobic residues in P2. Consequently, all
new substrates were designed with a Pro in the P3 position. For
the P2 position, we chose Nle, which gave the fastest rates of
hydrolysis in the screen, and Nle was arbitrarily chosen for the
P4 position to yield Ac-Nle-Pro-Nle-Asp-amc. We further
synthesized a second fluorogenic peptide, Ac-Gly-Pro-Leu-
Asp-amc.
The results of the PS-SCL screen predict that Ac-GPLD-amc
would be cleaved at 2–3-fold slower rates than Ac-nLPnLD-
amc, largely because Nle in the P2 position allowed at least
2-fold faster cleavages than Leu. Indeed, Ac-GPLD-amc was
hydrolyzed by 26 S proteasomes from rabbit muscle 2.5–3-fold
slower than Ac-nLPnLD-amc (Table I). Remarkably, Ac-
nLPnLD-amc was cleaved 30-fold faster than Ac-YVAD-amc
and Ac-GPLD-amc 12-fold faster than Ac-YVAD-amc (Table I).
Unfortunately, these substrates all showed high Km values
(500 M or higher) (16), which did not allow accurate meas-
urements of Vmax values. To show that the cleavage of these
substrates is indeed carried out by the caspase-like sites, we
used a mutant of the yeast proteasome in which the catalytic
threonine of the 1 subunit responsible for caspase-like activity
was changed to alanine. This mutation (1T1A) completely
abolished the cleavage of Z-LLE-na (37, 38) and blocked hy-
drolysis of Ac-nLPnLD-amc and Ac-GPLD-amc (Table I) as
well. Therefore, these substrates are specific for the caspase-
like sites. The HPLC analysis of the cleaved substrates re-
vealed the only fluorescent product for each reaction was free
AMC (Fig. 2). Thus, in contrast to the commonly used sub-
strates of the caspase-like sites, Z-LLE-na and Ac-YVAD-amc,
our new substrates are cleaved exclusively at the Asp-amc
bond.
The caspase-like sites can cleave not only after aspartic acid
but also after glutamic acid. In fact, this activity was defined
originally as postglutamyl peptide hydrolase or PGPH sites (6).
They also cleave after leucines and are largely responsible for
the “branched chain amino acid-preferring” (BrAAP) activity
(5, 38–41). There have been no studies of the relative prefer-
ences for aspartate, glutamate, and branched chain residues in
substrates with identical P4-P2 residues and the same fluoro-
genic reporter group. To make such a comparison and further
characterize the specificity of these sites, peptides Ac-GPLE-
amc, Ac-GPLL-amc, and Ac-APnLL-amc were synthesized. Ac-
GPLE-amc was cleaved by mammalian 26 S proteasomes and
yeast 20 S proteasomes at half the rate of Ac-GPLD-amc cleav-
age (Table I). This reaction was completely blocked by the
1T1A mutation, confirming that hydrolysis is carried out by
the caspase-like sites. Thus, these sites are indeed more
“caspase-like” (i.e. aspartate-preferring) than “postglutamyl
peptide hydrolase” in their specificity.
The two substrates with leucines in P1 were hydrolyzed by
mammalian 26 S proteasomes at half the rate of similar sub-
strates with Asp in P1, and Ac-GPLL-amc was cleaved even
faster than Ac-GPLE-amc (Table I). Cleavage of these BrAAP
substrates by the yeast particles was not blocked by the inac-
tivating mutation in the caspase-like sites, indicating that an-
other site(s) (most likely the chymotrypsin-like) is responsible
for this activity (Table I).
To test which active sites in mammalian proteasomes cleave
these substrates, we used selective inhibitors of different active
sites (Table II). Covalent inhibitors of the chymotrypsin- and
trypsin-like sites, NLVS and AEBSF, had very little effect on
hydrolysis by 26 S proteasomes of substrates containing Asp in
P1 (Table II), and even this inhibition could be due to partial
modification of the caspase-like sites by these inhibitors. In
contrast, cleavages after aspartates were inhibited by more
than 90% by the inhibitors of the caspase-like sites, peptide
epoxyketone YU102 (19) and the specific peptide aldhehydes
developed in this study (Table III; see below). Cleavage of the
substrate with glutamic acid in P1 by the 20 S proteasomes was
sensitive to the same inhibitors as was cleavage of Asp-contain-
ing peptides (data not shown). These data are in agreement
with findings with yeast mutants (Table I) that postaspartic
and postglutamic cleavages are performed by the same sites in2 A. Kisselev, unpublished observations.
TABLE I
Cleavage of new substrates by the proteasomes
All substrates were at 100 M. The specific activity of 26 S protea-
somes is mean  range of two different enzyme preparations.
Substrate
Specific activity
26 S (muscle)
proteasome
20 S (yeast) proteasome
Wild type 1T1A
nmol/min*mg
Ac-YVAD-amc 3.5 0.11 0
Ac-nLPnLD-amc 113  2 6.6 0
Ac-GPLD-amc 42  3 2.4 0
Ac-GPLE-amc 19 1.1 0
Ac-GPLL-amc 28  3 3.1 3.1
Ac-APnLL-amc 62  8 5.0 4.1
FIG. 2. Ac-nLPnLD-amc and Ac-GPLD-amc are cleaved only at
Asp-amc bonds. Ac-nLPnLD-amc and Ac-GPLD-amc (each at 100 M)
were incubated with 20 S proteasomes from rabbit muscles (1.2 g/ml)
for 6.5 h at room temperature (in order to facilitate the detection of even
minor reaction products). Substrates incubated without proteasomes
served as control. Reaction mixtures were separated by HPLC on a
Vydac C18 (2.1  250 mm) column using fluorescent detection. Excita-
tion (380 nm) and emission (420 nm) wavelength were chosen to allow
detection of free AMC and amc-containing peptides. Buffer A was 10
mM sodium phosphate, pH 6.8, and buffer B was a mixture of 70%
acetonitrile and 30% A. The gradient was 10–50% B in 40 min, followed
by 50–70% B in 10 min. The flow rate was 0.2 ml/min. Peaks of
substrates and reaction product are indicated. Note that only a single
fluorescent peak of the product is observed, the retention time of which
corresponds to the retention time of free AMC (not shown).
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yeast and mammalian proteasomes. In sharp contrast with
data obtained with yeast particles, the cleavage of substrates
with leucines in P1 by mammalian 26 S (Table I) and 20 S (data
not shown) proteasomes showed similar sensitivity to the in-
hibitors as substrates with acidic residue in P1, indicating that
most of the postleucine cleavages are performed by the caspase-
like sites in mammalian proteasomes. Thus, the ability of the
caspase-like sites in mammalian proteasomes to cleave after a
hydrophobic residue (at least when a Pro residue is present in
the P3 position) is comparable with their PGPH activity. These
data also demonstrate an interesting difference in substrate
specificity of the caspase-like sites between yeast and mamma-
lian proteasomes.
New Inhibitors of the Caspase-like Sites—The information
about the specificity of the caspase-like sites obtained with PSL
was then used to design specific inhibitors of the caspase-like
sites. The majority of proteasome inhibitors are short peptides
with a threonine-reactive pharmacophore at their C terminus
(42). We chose an aldehyde as the pharmacophore because of
the simplicity of synthesis (compared with epoxyketones and
peptide boronates) and because aldehyde derivatives of the
aspartic acid are stable, unlike vinyl sulfones. We used the
sequence of the best substrate Ac-nLPnLD-amc as the basis for
peptide portions of the inhibitors. However, the bulky nor-
leucine in P4 was replaced by a smaller alanine residue to give
Ac-APnLD-al in order to decrease the chances that this com-
pound would bind to the chymotrypsin-like sites at high con-
centrations. Large hydrophobic residues in the P4 position of
the inhibitors tend to increase the potency of inhibitors toward
chymotrypsin-like sites, even when the P1 residue is not hy-
drophobic.3 Replacement of the Nle by Ala, according to the
results with PS-SCL, should not affect the affinity of the inhib-
itor for the caspase-like sites (Fig. 1c). In addition, because
substrates with the lowest Km and presumably the best affinity
for caspase-like site, Z-LLE-na and Z-LLE-amc, have a Z group
in the P4 position, we also synthesized another inhibitor,
Z-PnLD-al.
The two peptide aldehydes synthesized inhibited the
caspase-like activity of 26 S proteasomes from rabbit muscle
with Ki values of 0.4–1 M (Table III). As expected for peptide
aldehydes, these compounds are reversible inhibitors. Preincu-
bation of the proteasomes with these inhibitors followed by
dilution into substrate solution resulted in the immediate loss
of the inhibition by Z-PnLD-al. A much slower loss of inhibition
was seen after the removal of Ac-APnLD-al, with complete
recovery after 10–20 min (data not shown). With Z-PnLD-al,
the inhibition was also evident immediately after the addition
to the proteasome, but Ac-APnLD-al required several minutes
incubation to reach steady state inhibition (data not shown).
The chymotrypsin-like and trypsin-like sites were not inhibited
even at concentrations greater than 50 Ki (Fig. 3) or even 100
Ki (data not shown). In contrast, epoxyketone YU102 (Ac-
GPFL-ex), which was reported previously to be a selective
inhibitor of the caspase-like activity (19), showed 50% inhibi-
tion of the chymotrypsin-like activity at concentrations exceed-
ing its IC50 for the caspase-like activity only by 10-fold (Fig. 3).
Thus, both peptide aldehydes are more selective inhibitors of
the caspase-like sites than any agent previously described.
The inhibition of latent rabbit muscle 20 S proteasome by
these new inhibitors was 10-fold weaker than that of 26 S
proteasomes (Table III). It is believed that the 19 S regulatory
complex stimulates peptide hydrolysis in the 20 S core largely
by opening the channel in the 20 S -rings (14), although
additional allosteric effects have not been ruled out. To test
whether the greater potency of the inhibitor in 26 S protea-
somes is a consequence of the open channel, we measured the
Ki of the inhibitor under a variety of conditions that lead to gate
opening in the -rings. When channel opening in the 20 S
proteasomes was stimulated by the addition of the hydrophobic
peptide Suc-FLF-mna (16), the Ki value of both new inhibitors
of the caspase-like sites decreased almost to the level found
with the 26 S proteasomes (Table III). Similarly, in the yeast 20
S proteasomes, opening of the channels in the -ring by muta-
tion or by addition of the protein activator PA26 (15) signifi-
cantly enhanced the sensitivity of the caspase-like site to these
new peptide aldehydes (Table III). These treatments also in-
creased the degree of inhibition of the chymotrypsin-like site by
MG132 (Z-LLL-al) by 5–25-fold (data not shown). It is notewor-
thy that opening of the channel generally results in the lower
Km values of the substrates (16). These lower Ki values of the
open gate forms may simply reflect the fact that effective con-
centrations of inhibitors in these forms are higher than when
the gates are closed. Alternatively, opening of the channel in
the -ring may result in stronger binding of inhibitors and
substrates to the active sites.
PS-SCL results indicated that the P4-P2 preference of pro-
teasome (Fig. 1) is significantly different from that of caspases
(20). As expected from those observations, the peptide alde-
hydes synthesized in this work were weak inhibitors of
caspases, with Ki for different caspases ranging from 30 to 130
M (Table III). Also, the nanomolar inhibitor of caspase-1 Ac-
YVAD-al (33) inhibited the 26 S proteasome with a Ki of 40 M
(not shown).
Inhibitors of Caspase-like Sites Stimulate Peptide Cleavage
by the Trypsin-like Sites—While analyzing effects of these new
inhibitors of the caspase-like sites on two other peptidase ac-
tivities of the 26 S proteasome, we noticed that these com-
pounds increased the trypsin-like activity by 15–20% (Fig. 3).
This stimulation of cleavage of Boc-LRR-amc was reproducibly
observed in three different preparations of 26 S proteasomes.
In yeast 20 S proteasomes, Ac-APnLD-al caused a 50% increase
in the trypsin-like activity (Table IV), and a 2-fold activation by
epoxyketone YU102 was also observed (data not shown). In the
presence of the PA26 proteasome activator, the aldehydes stim-
ulated cleavage of Boc-LRR-amc (Table IV) and Z-ARR-amc3 T. N. Akopian and A. L. Goldberg, unpublished observations.
TABLE II
Effect of inhibitors of individual active sites on hydrolysis of
substrates by 26 S proteasomes
26 S proteasomes (0.15 mg/ml in the storage buffer) were preincu-
bated with inhibitors (1 M NLVS, 1 mM AEBSF, 15 M YU102, 25 M
Ac-APnLD-al, 50 M Z-PnLD-al) for 30 min at 37°C and then diluted
440-fold into 100 M solutions of substrates. In case of reversible alde-
hyde inhibitors (Ac-APnLD-al and Z-PnLD-al), substrate solutions also
contained the same concentrations of these inhibitors as those used for
preincubations with the proteasome. Inhibition was calculated by re-
lating the activity of inhibitor-treated proteasomes to the control pro-
teasomes treated in a similar fashion but in the absence of inhibitor.
Substrates
Inhibition
NLVS AEBSF YU102 Ac-APnLD-al Z-PnLD-al
% % % % %
New
Ac-nLPnLD-amc 4 25 89 99 99
Ac-GPLD-amc 5 22 89 100 100
Ac-GPLL-amc 7 19 85 95 95
Ac-APnLL-amc 12 21 84 89 91
Standard
Suc-LLVY-amca 81 26 29 24 12
Boc-LRR-amcb 7 98 0 0c 0c
a A standard substrate for the chymotrypsin-like activity.
b A standard substrate for the trypsin-like activity.
c 19% activation of the trypsin-like activity by acidic peptide alde-
hydes was observed (see also Fig. 3).
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(not shown) by 3-fold. This stimulation in the yeast (Fig. 4) and
mammalian (data not shown) proteasomes was entirely due to
an increase in the Vmax (Fig. 4).
To test whether this activation of the trypsin-like activity is
indeed due to the binding of inhibitors to the caspase-like site
and not to a distinct regulatory site (16), we studied whether
blocking inhibitor binding to the caspase-like site would pre-
vent this allosteric stimulation. As mentioned above, mutation
of catalytic threonine of the 1 subunit in yeast S. cerevisiae
proteasomes into an alanine completely eliminated the
caspase-like activity (37, 38). This 1T1A mutant fails to cleave
off the propeptide, which was shown by x-ray diffraction to
occupy the substrate-binding site (12). We therefore compared
the effects of inhibitors of the caspase-like sites on the trypsin-
like activity in the wild type yeast 20 S proteasomes and in the
1T1A mutant, where they could not bind to the caspase-like
sites.
Although the peptide aldehyde Ac-APnLD-al stimulated the
trypsin-like activity of the wild-type proteasomes 3-fold at all
concentrations of two different substrates tested, it failed to
cause a significant increase in the 1T1A mutant (Fig. 4).
Interestingly, the basal activity of the mutant was 2-fold higher
than that of the wild type, probably because of the presence of
the propeptide in the active site. Thus, occupancy of the
caspase-like sites by peptides allosterically stimulates peptide
hydrolysis by the trypsin-like sites.
Occupancy of the Caspase-like Sites Does Not Prevent Allo-
steric Inhibition of Chymotrypsin-like Sites by Acidic Pep-
tides—A substrate of the caspase-like site, Z-LLE-na, alloster-
ically inhibits the chymotrypsin-like activity in the 26 and 20 S
particles (5). Because the Ki for this allosteric inhibition resem-
bled the Km of the caspase-like site for this substrate, we
concluded that this inhibition was due to the binding of this
acidic peptide to the caspase-like sites. Myung et al. (19) and
Schmidtke et al. (18) confirmed these observations but demon-
strated that inhibitors of the caspase-like site do not prevent
these allosteric effects of its substrate. Therefore, they con-
cluded that this acidic peptide acts by binding to a noncatalytic
site.
To resolve this controversy, we tested whether occupancy of
the caspase-like site by more selective inhibitors developed in
this study or by the 1 propeptide could prevent allosteric
inhibition of the chymotrypsin-like activity by substrates of the
caspase-like site. The two inhibitors developed in this study,
which by themselves did not affect the chymotrypsin-like ac-
tivity of mammalian 26 S proteasomes (Fig. 3), did not prevent
the allosteric inhibition of the chymotrypsin-like activity by
Z-LLE-na (Fig. 5). Similarly, this substrate of the caspase-like
TABLE III
New peptide aldehyde inhibitors of the caspase-like sites
Enzyme Source Addition
Ki
Ac-APnLD-al Z-PnLD-al
M
Proteasomesa
26 S Rabbit muscle 0.40  0.07 1.0  0.1
20 S Rabbit muscle 16.3  4.7 12.1  4.7
20 S Rabbit muscle Suc-FLF-mna 1.34  0.12 2.7  1.1
20 S Yeast 20  3 21  7
20 S Yeast PA26 1.6  0.6 3.9  1.5
N3–20 S Yeast 2.7  0.8 7.0  2.2
Caspase-1 83 30
Caspase-3 45 22
Caspase-7 133 126
a Inhibition of the proteasomes’ caspase-like activity was measured using Ac-nLPnLD-amc as substrate. Values are means  S.D. of three
experiments for 26 S proteasomes and mean  range of two experiments for 20 S proteasomes.
FIG. 3. Effect of peptide aldehydes and epoxyketone on different active sites of 26 S proteasomes from rabbit muscles. The
chymotrypsin-like, caspase-like, and trypsin-like activities were assayed with Suc-LLVY-amc, Ac-nLPnLD-amc, and Boc-LRR-amc (each at 100
M), respectively. To measure the effect of peptide aldehydes, 26 S proteasomes were added to a mixture of aldehydes and substrates, and reaction
velocities in the presence and absence of inhibitor were determined from the steady state slopes of the reaction progress curves. 15–20% stimulation
of the trypsin-like activity by 50 M Z-PnLD-al and Ac-APnLD-al was reproducibly observed with three different preparations of 26 S proteasomes.
To measure effects of irreversible epoxyketone YU102 (Ac-GPFL-ex), 26 S proteasomes (0.2 mg/ml) were preincubated with YU102 for 15 min and
then diluted 930-fold in substrate solutions containing no inhibitor.
TABLE IV
Occupancy of the caspase-like sites in yeast proteasomes
stimulates the trypsin-like activity
The trypsin-like activity was assayed using 100 M Boc-LRR-amc as
the substrate. Ac-APnLD-al was at 50 M.
Proteasome
Specific activity Increase
by
inhibitor
Increase by
propeptideControl Ac-APnLD-al
nmol/min*mg -fold -fold
20 S (WT) 2.2 3.4 1.5 1.3
20 S (1T1A) 2.9 3.1 1.1
20 S (WT) 
PA26
20.1 64.3 3.2 2.2
20 S (1T1A)
 PA26
43.8 41.7 1
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site was able to inhibit the chymotrypsin-like activity in the
1T1A mutant of yeast 20 S proteasomes where the caspase-
like site was occupied by the uncleaved propeptide. Thus, oc-
cupancy of the caspase-like site does not prevent its substrate
from inhibiting the chymotrypsin-like site. Therefore, acidic
peptides must be exerting their allosteric effects by two distinct
mechanisms. They inhibit the chymotrypsin-like activity by
binding to a noncatalytic, regulatory site and activate trypsin-
like sites by binding to the caspase-like sites.
DISCUSSION
Specificity of the Caspase-like Sites—Positional scanning
combinatorial libraries have been used to characterize the sub-
strate specificity of a variety of proteases (20–23), including
that of the 20 S proteasome and its modulation by PA28 acti-
vators (24). By using selective inhibitors of the chymotrypsin-
and trypsin-like site of the proteasome, we were able to show
that the vast majority of cleavages in the libraries with Asp in
P1 position are carried out by the caspase-like sites (an issue
not addressed in the previous studies) (24). The preference for
hydrophobic residues in P2 position was unexpected, because
no obvious binding pocket for the P2 residue could be identified
from x-ray diffraction analysis of complexes of proteasomes
with inhibitors (4, 8).
Interestingly, the positional preference of rabbit muscle 20 S
proteasomes (Fig. 1) differed from that of human erythrocyte
20 S proteasomes found with the similar PS-SCL library (24).
These differences cannot be due to the presence of interferon-
inducible subunits (43) in any of the preparations, because
proteasomes from muscle and erythrocytes lack these subunits
(44). Furthermore, the presence of these subunits does not
affect the preference for P2–P4 positions (data not shown). A
possible reason for differences could be post-translational mod-
ifications due to aging of proteasomes from erythrocytes. The
half-life of proteasomes in red blood cells is significantly longer
than in any other cell types or tissues.
In the presence of PA28, the preferences of erythrocyte
proteasomes for the P4–P2 positions resembled more closely the
preferences observed in our study (24). Since the best docu-
mented effect of PA28 on 20 S proteasomes is the opening of the
channel in the -rings (15), these changes could be caused by
peptides’ different abilities to traverse this channel in the ab-
sence of PA28. To test whether our results (Fig. 1) obtained with
the latent muscle 20 S proteasomes could also be affected by
different abilities of the peptides to enter the particle, we re-
peated the screen with PS-SCL in the presence of SDS and
hydrophobic peptides, which stimulate opening of the channel
(16). Because no differences were found (data not shown), we
conclude that we determined the true specificity of the caspase-
like sites and that the state of the channel does not affect the
cleavage preferences established with this library. This result
suggests also that PA28 changes the pattern of preferences of
proteasomes (24) not because of the opening of the gate but
rather by causing yet to be defined alterations to the active sites
as suggested by Rechsteiner and colleagues (24, 45).
Although the term “caspase-like” seems most appropriate for
the proteasome active sites cleaving after acidic residues, the
subsite preferences of these sites in the P2–P4 positions are
different from those of the majority of caspases (20). Most
caspases prefer acidic residues or their amides in the P3 posi-
tion (20), whereas the proteasome shows a preference for pro-
line, alanine, and large aliphatic residues (Fig. 1b). Finally,
caspases prefer histidine, threonine, or valine in the P2 posi-
tion (depending on the class), whereas proteasomes show a
preference for bulky hydrophobic residues.
The most striking differences between the subsite prefer-
ences of caspases and caspase-like sites in the proteasome are
in the P1 position. Caspases cleave exclusively after aspartic
acid residues (35), whereas caspase-like sites in proteasomes
can also cleave after glutamic acid and even leucine residues
(38, 40, 41). Indeed, this ability of proteasomes to cleave after
glutamic acid residues was the activity initially discovered by
Wilk and Orlowski (reviewed in Ref. 6) and was the basis for it
being termed PGPH until we found that it cleaves after aspar-
tates as well (5). The present study compared the ability of
proteasomes to cleave after glutamic and aspartic acid residues
following identical P4–P2 residues and preceded by the same
fluorogenic group. Both 26 S proteasomes from rabbit muscles
and yeast 20 S proteasomes cleave after aspartates 2-fold faster
than after glutamates (Table I) and are indeed more “caspase-
like” than PGPH. Furthermore, the PGPH activity of these
sites in rabbit 26 S proteasomes is actually lower than their
ability to cleave after leucines (Table I), sometimes referred to
as BrAAP activity (39). This activity has actually been consid-
FIG. 4. Occupancy of the caspase-
like sites stimulates the trypsin-like
activity. Hydrolysis of Boc-LRR-amc by
wild-type yeast 20 S proteasomes and its
1T1A mutant (1 g/ml each) was meas-
ured in the presence of PA26 (1 g/ml)
and in the presence or absence of 100 M
Z-PnLD-al. Similar results were obtained
with another substrate of the trypsin-like
site, Z-ARR-amc.
FIG. 5. Substrate of the caspase-like sites inhibits the chymo-
trypsin-like activity even when their binding to the caspase-like
sites is blocked by inhibitor or propeptide. Inhibition of the chy-
motrypsin-like activity of mammalian 26 S proteasomes and yeast 20
S-PA26 complexes by Z-LLE-na is not affected by the occupancy of the
caspase-like site by inhibitors Ac-APnLD-al (50 M) and Z-PnLD-al (100
M) or uncleaved propeptide (1T1A mutant). The chymotrypsin-like
activity was assayed with 100 M Suc-LLVY-amc.
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ered to be catalyzed by a distinct active site based on kinetic
studies (39), but structural studies and site-directed mutagen-
esis failed to reveal the presence of such a site (4, 38). Thus, the
“caspase-like” site is more accurate term than PGPH.
We found some differences in the specificity of caspase-like
sites between mammalian and yeast proteasomes. Two sub-
strates with Leu in P1 and Pro in P3 were cleaved by caspase-
like sites in mammalian proteasomes (Table II). In contrast,
the rates of cleavage of these substrates by yeast proteasomes
were not affected by the inactivation of the caspase-like sites by
mutation, indicating that they are cleaved by some other site,
perhaps the chymotrypsin-like sites (Table I). We also noticed
that the peptide epoxyketone YU102 (Ac-GPFL-ek), which also
has Leu in P1 and Pro in P3, is a much less potent inhibitor of
the caspase-like sites in yeast than in mammalian proteasomes
(data not shown). In contrast, peptide aldehydes with acidic
residues in P1 showed a similar inhibition of the yeast and
mammalian proteasomes (Table III). Thus, the yeast protea-
some is not always an adequate model for mammalian
particles.
New Inhibitors of the Caspase-like Sites—PS-SCL are excel-
lent tools for the design of enzyme inhibitors (35). In this study,
analysis of the specificity of the caspase-like sites by this ap-
proach allowed us to generate potent and selective inhibitors of
the caspase-like sites without the laborious synthesis and pu-
rification of numerous compounds. In fact, it was possible by
synthesis of just three compounds (the third compound, Z-
PnLE-al, had similar potency as Z-PnLD-al), to create more
potent and specific inhibitors than peptide epoxyketone YU102
(Ac-GPFL-ex) (Fig. 3), whose development required synthesis
of about 20 compounds (19).
Proteasomes play an essential role in the generation of MHC
class I antigenic peptides and their N-terminally extended
precursors (see Ref. 43 for a review). Organs of the immune
system contain a different set of proteasomes, called immuno-
proteasomes. In these particles, catalytic subunits LMP2,
LMP7, and MECL replace subunits 1 (Y), 5 (X), and 2 (Z),
catalytic subunits of constitutive proteasomes (44, 46). Expres-
sion of immunoproteasome subunits is also induced by inter-
feron-, a cytokine that stimulates antigen presentation (43).
Immunoproteasomes have higher chymotrypsin-like, trypsin-
like activity and lower caspase-like activity. These observa-
tions suggest an important role of the caspase-like sites in the
generation or, more likely, destruction of antigenic peptides.
This hypothesis could not be tested due to lack of sufficiently
selective cell-permeable inhibitors of caspase-like sites and ap-
propriate genetic tools in mammalian cells. Compounds devel-
oped in this study are sufficiently selective to address this
question, but their ability to inhibit capase-like sites of the
proteasomes in cells could not be tested for several reasons.
Substrates developed in this study are not cell-permeable (data
not shown), and because caspase-like sites are not essential for
overall protein breakdown (37, 47), there is no easy readout for
the inhibition of these sites in cells by compounds that do not
form a stable covalent bond with an active site threonine.
Stimulation of the Trypsin-like Activity by Inhibitors of the
Caspase-like Sites—Surprisingly, peptide aldehyde inhibitors
of the caspase-like sites enhanced the trypsin-like activity of
proteasomes (Fig. 3), especially in yeast, where this effect was
much stronger than in mammals (Table IV). When binding of
an inhibitor to the caspase-like site was prevented by the
uncleaved propeptide, no stimulation of the trypsin-like activ-
ity was observed. Furthermore, the presence of a propeptide by
itself stimulated the trypsin-like activity 2-fold (see Table IV,
Fig. 4, and Ref. 38). Thus, occupancy of the caspase-like sites
allosterically stimulates the trypsin-like activity.
In the presence of the PA26 complex, the allosteric stimula-
tion of the trypsin-like activity in yeast 20 S proteasomes
increased from 1.5- to 3-fold (Table IV). The simplest explana-
tion for this result would be that, because these aldehydes are
weaker inhibitors of free 20 S proteasomes than of 20S-PA26
complexes (Table III), the caspase-like sites are not fully occu-
pied by inhibitors in 20 S proteasomes at the concentrations
used in the experiments (50 M). However, in the 1T1A mu-
tant, where all active sites are occupied by the propeptide,
PA26 enhances the allosteric effect of the propeptide in a sim-
ilar fashion as it does with the allosteric effects of the inhibitor
(Table IV).
A more likely explanation of the stronger stimulatory effect
of the inhibitors in the PA26–20 S complexes is the open state
of the channel in the -rings. PA26 was shown by x-ray diffrac-
tion to open this channel in the latent 20 S proteasomes (15).
Opening of the channel by PA26, as well as by mutation,
hydrophobic peptides, low concentrations of SDS, or the 19 S
regulatory complexes significantly increases the rates of pep-
tide hydrolysis by all three active sites. Therefore, substrate
entrance into the proteolytic chamber is a rate-limiting step in
their hydrolysis by the latent 20 S proteasomes (13, 16). We
previously demonstrated that stimulation by hydrophobic pep-
tides of peptide cleavages by all three active sites was com-
pletely abolished in the presence of PA26 (16). In contrast, the
allosteric activation of the trypsin-like sites by occupancy of the
caspase-like sites observed in this study behaved in the oppo-
site fashion (i.e. it was stronger when the channel was open). In
other words, the effect of the occupancy of caspase-like sites on
trypsin-like activity in yeast 20 S proteasomes is stronger when
cleavages at the active sites are rate-limiting and weaker when
the rates of cleavages depend on the ability of substrates to
traverse the channels. This observation provides further evi-
dence that acidic peptides exert allosteric effects on the trypsin-
like sites rather than stimulate them indirectly as hydrophobic
peptides do (16).
Substrates of the Caspase-like Sites Inhibit the Chymotryp-
sin-like Site by Binding to a Noncatalytic Site—In contrast to
FIG. 6. Different regulatory effects
of peptides on proteasome active
sites.
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their effects on the trypsin-like sites, inhibitors of the caspase-
like sites had little effect on the chymotrypsin-like activity.
Furthermore, the results of this (Fig. 5) and two previous
studies (18, 19) clearly demonstrate that such inhibitors do not
prevent allosteric inhibition of the chymotrypsin-like sites by
substrates of the caspase-like sites. In addition, these acidic
peptides are able to inhibit the chymotrypsin-like activity when
their binding to the caspase-like site is blocked by the un-
cleaved propeptide (Fig. 5). Therefore, substrates of the
caspase-like site decrease the chymotrypsin-like activity by
binding to a distinct noncatalytic site.
Cooperative binding of hydrophobic peptides to several non-
catalytic regulatory sites on the latent 20 S proteasome stim-
ulates peptide hydrolysis by all three active sites (16). Several
observations indicate significant differences between these two
effects of peptides and suggest that sites to which hydrophobic
peptides bind are functionally quite different from the sites
interacting with acidic peptides. First, hydrophobic peptides
stimulate all three peptidase activities, whereas acidic peptides
inhibit only the chymotrypsin-like activity. Second, hydropho-
bic peptides act only on latent 20 S proteasomes and not on 26
S proteasomes or 20 S-PA28 complexes. In contrast, acidic
peptides inhibited chymotrypsin-like activity in all forms of
proteasome tested. Third, acidic peptides inhibit protein break-
down by the proteasomes, whereas hydrophobic peptides have
little effect. These functional differences of two effects also
suggest that regulatory sites responsible for them are topolog-
ically distinct, but this suggestion can be confirmed only after
both sites are localized in the particle. The mechanism by
which acidic peptides inhibit chymotrypsin-like activity or pro-
tein breakdown by proteasomes is unclear.
In summary, we have distinguished three different regulatory
effects of peptides in proteasomes (Fig. 6). First, binding of hy-
drophobic peptides to multiple noncatalytic sites stimulates
opening of the channels in the -rings and thus enhances peptide
hydrolysis by all active sites in the latent 20 S proteasome (16).
Second, binding of acidic peptides to a distinct noncatalytic site
inhibits the chymotrypsin-like activity and protein breakdown by
proteasomes. Finally, occupancy of the caspase-like sites stimu-
lates the trypsin-like activity of the proteasome.
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